AXDX - Accelerate Diagnostics, Inc.
| Previous Close | 16.16 |
| Open | 16.12 |
| Bid | 16.43 x 900 |
| Ask | 16.48 x 800 |
| Day's Range | 15.83 - 16.48 |
| 52 Week Range | 10.23 - 24.00 |
| Volume | 279,552 |
| Avg. Volume | 213,473 |
| Market Cap | 898M |
| Beta (5Y Monthly) | 2.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.57 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.67 |
- American City Business Journals
Accelerate Diagnostics CEO plans to retire in January; replacement named
Longtime CEO Lawrence Mehren has said he intends to retire at the end of January 2020 but will continue in a transitional part-time role for two years.
- PR Newswire
Accelerate Diagnostics to Participate in 31st Annual Piper Jaffray Healthcare Conference in New York on December 4, 2019
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Larry Mehren, chief executive officer, will participate in a 25-minute question and answer session at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 4, 2019 at 3:30 p.m. Eastern Time. Jack Phillips, chief operating officer, and Steve Reichling, the company's chief financial officer, will accompany Mr. Mehren.
- PR Newswire
Accelerate Diagnostics Announces Executive Transition: Lawrence Mehren to Retire as Chief Executive Officer; Jack Phillips Appointed as Successor
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that Lawrence Mehren will retire from the company. Jack Phillips, the company's Chief Operating Officer, has been unanimously appointed by the board to the position, effective February 1, 2020. Mr. Mehren will support the transition process, remaining as a key advisor to the company through 2021. This move is the culmination of a succession plan initiated in 2018 by Mr. Mehren and the board to prepare the company for the next phase of commercial growth.
- Simply Wall St.
Is Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) CEO Paid Enough Relative To Peers?
Larry Mehren has been the CEO of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) since 2012. This report will, first...
- PR Newswire
Accelerate Diagnostics Appoints Louise Francesconi to its Board of Directors
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that Louise Francesconi has been appointed to the company's Board of Directors.
- Thomson Reuters StreetEvents
Edited Transcript of AXDX earnings conference call or presentation 7-Nov-19 9:30pm GMT
Q3 2019 Accelerate Diagnostics Inc Earnings Call
- Benzinga
12 Stocks With Short Ratios Above 50
Short interest can be an extremely helpful too for traders looking to get a feel for how a stock might react to a catalyst or gauge the overall bullish or bearish sentiment in a stock. Stocks with extremely ...
- American City Business Journals
Seven Arizona companies ranked among fastest growing by Deloitte
The companies on the 2019 Technology Fast 500 list are based on percentage fiscal year revenue growth from 2015 to 2018.
- Zacks
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Accelerate Diagnostics Reports Third Quarter 2019 Financial Results
TUCSON, Ariz. , Nov. 7, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2019 . "Our placement and revenue ...
- PR Newswire
Accelerate Diagnostics Appoints Roland Diggelmann to its Board of Directors
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John Patience, Chairman of the Board of Directors. "Roland brings extensive experience from his decades of successful diagnostics company leadership.
- Zacks
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Is Accelerate Diagnostics Inc (AXDX) Going To Burn These Hedge Funds ?
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- PR Newswire
Accelerate Diagnostics Schedules Call to Review Third Quarter 2019 Results
TUCSON, Ariz. , Oct. 17, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that it will report financial results for the third quarter of 2019 after the market close on Thursday, ...
- PR Newswire
Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
"We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest™ BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations. The first of the studies is RAPIDS-GN (ClinicalTrials.gov # NCT03218397), a randomized controlled trial conducted at Mayo Clinic and UCLA. RAPIDS-GN focused on Gram-negative bacteremia and randomized patients to be tested by the BC kit or legacy methods. The study met the primary endpoint of therapy optimization, reporting time to first Gram-negative antibiotic change a full 24 hours sooner than legacy methods (17.4 hours vs. 42.1 hours, p
- Investor's Business Daily
Just Two Stocks Turned Pennies Into Billions
The idea of turning pocket change into a billion bucks is alluring. But this mirage of penny stocks is also nearly a complete fantasy.
- Zacks
Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- PR Newswire
Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies
TUCSON, Ariz., Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. The first of these studies is the ARLG-sponsored RAPIDS-GN clinical study conducted at Mayo Clinic and UCLA.
- Thomson Reuters StreetEvents
Edited Transcript of AXDX earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Accelerate Diagnostics Inc Earnings Call
Motley FoolAccelerate Diagnostics (AXDX) Q2 2019 Earnings Call Transcript
AXDX earnings call for the period ending June 30, 2019.
- Zacks
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Accelerate Diagnostics Names Jack Phillips Chief Operating Officer
TUCSON, Ariz., Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Jack Phillips has been appointed Chief Operating Officer. Mr. Phillips joins Accelerate from Roche Diagnostics, the world's leading diagnostics company. Lawrence Mehren, President and Chief Executive Officer of Accelerate Diagnostics, commented, "We are thrilled to have an accomplished commercial leader of Jack's caliber join our team. This is an exciting time for Accelerate as we approach an inflection point in our commercial growth.
- PR Newswire
Accelerate Diagnostics Reports Second Quarter 2019 Financial Results
TUCSON, Ariz. , Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2019 . "We achieved mixed results in ...
- Simply Wall St.
Some Accelerate Diagnostics (NASDAQ:AXDX) Shareholders Are Down 19%
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
- Zacks
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
